about
Epidemiology of intrafamilial inflammatory bowel disease throughout EuropeClinical Outcomes of Golimumab as First, Second or Third Anti-TNF Agent in Patients with Moderate-to-Severe Ulcerative Colitis.Effectiveness of adalimumab for the treatment of ulcerative colitis in clinical practice: comparison between anti-tumour necrosis factor-naïve and non-naïve patients.Frequency, predictors, and consequences of maintenance infliximab therapy intensification in ulcerative colitis.Infliximab in ulcerative colitis: real-life analysis of factors predicting treatment discontinuation due to lack of response or colectomy: ECIA (ACAD Colitis and Infliximab Study).Incidence, Clinical Characteristics, and Management of Psoriasis Induced by Anti-TNF Therapy in Patients with Inflammatory Bowel Disease: A Nationwide Cohort Study.Involvement of the fas system in hepatitis C virus recurrence after liver transplantation.Apoptosis mediated by the Fas system in the fulminant hepatitis by hepatitis B virus.Erratum to: Effectiveness of adalimumab for the treatment of ulcerative colitis in clinical practice: comparison between anti-tumour necrosis factor-naïve and non-naïve patients.Short and long-term effectiveness and safety of vedolizumab in inflammatory bowel disease: results from the ENEIDA registryRecomendaciones del Grupo Español de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa (GETECCU) y de la Confederación de Asociaciones de Enfermedad de Crohn y Colitis Ulcerosa (ACCU) para el manejo de los aspectos psicológicos en la enfermedad inEpidemIBD: rationale and design of a large-scale epidemiological study of inflammatory bowel disease in Spain.Granulocyte elastase in cirrhotic patients with spontaneous bacterial peritonitisParathyroid hormone-related protein in liver cirrhosis[Chylous ascites in cirrhotic and non-cirrhotic patients][Soluble Fas in acute rejection in patients with liver transplantation. Response to treatment]Plasma leptin and TNF-alpha levels in chronic hepatitis C patients and their relationship to hepatic fibrosisCleaning and disinfection of gastrointestinal endoscopes. Comparative analysis of two disinfectants[Comparison of esophageal stenoses produced by endoscopic sclerotherapy versus variceal ligation]Influence of anti-TNF therapy on bone metabolism in patients with inflammatory bowel diseaseEffectiveness and Safety of the Sequential Use of a Second and Third Anti-TNF Agent in Patients With Inflammatory Bowel Disease: Results From the Eneida RegistryAdalimumab or Infliximab for the Prevention of Early Postoperative Recurrence of Crohn Disease: Results From the ENEIDA RegistryPrevalence and Factors Associated With Fatigue in Patients With Inflammatory Bowel Disease: A Multicentre StudyClinical Characteristics, Associated Malignancies and Management of Primary Sclerosing Cholangitis in Inflammatory Bowel Disease Patients: A Multicentre Retrospective Cohort StudyCrohn's Disease and Immunosupressive Treatment: Hepatosplenic Lesions as an Atypical Case of Bartonella henselaePerioperative management and early complications after intestinal resection with ileocolonic anastomosis in Crohn's disease: analysis from the PRACTICROHN studyReal-world short-term effectiveness of ustekinumab in 305 patients with Crohn's disease: results from the ENEIDA registryEffectiveness and Safety of the Switch from Remicade® to CT-P13 in Patients with Inflammatory Bowel DiseaseChanges in the requirement for early surgery in inflammatory bowel disease in the era of biological agentsSerial Tuberculin Skin Tests Improve the Detection of Latent Tuberculosis Infection in Patients With Inflammatory Bowel Disease
P50
Q26999295-E6669BC5-5BB3-4DE7-B981-DAEB0C0A9FE5Q38696735-94066C5E-28E1-433E-AEF5-669459FF88F0Q39306418-515714D1-F2F1-4C80-9A32-FAE0F1DF75A6Q40580152-22823064-93CD-4A60-8F1D-49AAADF4269DQ40708429-EEEEE48F-15EB-43E0-8868-3C8E3BBE3E5FQ40876904-9CD3105B-2DDB-467C-957E-5196CFF08627Q43000157-771336C9-5D22-4BA2-A7E9-E92B8332A291Q45733507-86A23CEA-03A4-4BC1-BF3F-2B9D5DC2C6E4Q48198540-F9E3B55B-AAA7-4241-BE7F-6E7A56EE295FQ57051384-334DE845-5D52-4EF4-BB9F-BA051BAFF9B4Q61349523-74B685E0-F0F2-4FCB-B47F-1BCC2A2943E8Q64983198-B19A6A59-9A93-4710-A57E-7962995CA342Q73149069-B20BEA03-02A8-4846-B375-6C16EF1515C6Q73663063-179A0783-1BC7-4AB0-A029-401E1D5237A5Q73696368-6AF7F8BF-159F-4DFA-8F00-22186EEFBD98Q74022324-97BB707C-7886-4DC8-B372-6E7A24FBA474Q74522669-B170FD00-77C5-4468-998D-4CFABE88C826Q78224025-B335953C-16A5-442E-82B7-DDF091448FD6Q79385646-FDAF291C-CEEF-49A2-B2D8-3905A9B6863EQ89219875-EA6A3AD8-6956-4417-AD22-80652975AD58Q90027963-C51D6057-4727-4208-B712-AFCBCDEDAE2EQ90056825-7B9499A0-B510-4A88-9AF9-2877C66E10C8Q91355368-E74B05D8-6BE9-41FD-A8CB-F48C42980A68Q91822148-698CDBDD-D289-4DCA-8EA6-5ED40AC32F3AQ92466677-9D151152-8B0F-444D-A903-D3697A31DD16Q92888132-390F3EEF-764F-4E23-BE21-25C13D1B0ED5Q92925396-E11AD9CC-0D18-438B-B42E-DFE499F5BAD4Q93046746-1AF4380D-B4E1-4FBC-89FC-98FB6A2E5DB4Q94462977-2AB64328-E31F-4050-8DC1-6EBB4F419BCDQ95725587-D2634A59-44B2-4519-8915-AF58A2D444B6
P50
description
hulumtuese
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Montserrat Rivero
@ast
Montserrat Rivero
@en
Montserrat Rivero
@es
Montserrat Rivero
@nl
type
label
Montserrat Rivero
@ast
Montserrat Rivero
@en
Montserrat Rivero
@es
Montserrat Rivero
@nl
prefLabel
Montserrat Rivero
@ast
Montserrat Rivero
@en
Montserrat Rivero
@es
Montserrat Rivero
@nl
P106
P21
P31
P496
0000-0002-5834-1559